Progress of delivery methods for CRISPR-Cas9. (3rd August 2022)

• Record Type: Journal Article
• Authors: Yang, Wu; Yan, Jiaqi; Zhuang, Pengzhen; Ding, Tao; Chen, Yu; Zhang, Yu; Zhang, Hongbo; Cui, Wenguo
• Is Part Of: Expert opinion on drug delivery. Volume 19:Number 8(2022)
• Page Start: 913
• Page End: 926
• Publication Date: 2022-08-03
• Subjects: CRISPR -- Cas9 -- gene editing -- drug delivery -- review; Drug delivery devices -- Periodicals; Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1080/17425247.2022.2100342
• Languages: English
• ISSNs: 1742-5247

Abstract

ABSTRACT: Introduction: Gene therapy is becoming increasingly common in clinical practice, giving hope for the correction of a wide range of human diseases and defects. The CRISPR/Cas9 system, consisting of the Cas9 nuclease and single-guide RNA (sgRNA), has revolutionized the field of gene editing. However, efficiently delivering the CRISPR-Cas9 to the target organ or cell remains a significant challenge. In recent years, with rapid advances in nanoscience, materials science, and medicine, researchers have developed various technologies that can deliver CRISPR-Cas9 in different forms for in vitro and in vivo gene editing. Here, we review the development of the CRISPR-Cas9 and describe the delivery forms and the vectors that have emerged in CRISPR-Cas9 delivery, summarizing the key barriers and the promising strategies that vectors currently face in delivering the CRISPR-Cas9. Areas covered: With the rapid development of CRISPR-Cas9, delivery methods are becoming increasingly important in the in vivo delivery of CRISPR-Cas9. Expert opinion: CRISPR-Cas9 is becoming increasingly common in clinical trials. However, the complex nuclease and protease environment is a tremendous challenge for in vivo clinical applications. Therefore, the development of delivery methods is highly likely to take the application of CRISPR-Cas9 technology to another level.